GlassScriptPhysician profile
Philip R Henry
NPI 1023097946
$9,246.31
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,855 · 2020: $1,624 · 2021: $2,127 · 2022: $1,494 · 2023: $1,905 · 2024: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,385.07 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $925.33 | 2019-2024 | |
| Novo Nordisk INC | $832.62 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $691.01 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $676.39 | 2019-2023 | Prolia, Evenity |
| Pfizer INC. | $538.83 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $478.59 | 2019-2024 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $390.28 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.06 | 2019-2023 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.43 | 2019-2023 | Trulance, Xifaxan |
| Teva Pharmaceuticals USA, INC. | $238.14 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $233.14 | 2022-2024 | Livalo, Seglentis |
| Sanofi-Aventis U.S. LLC | $222.03 | 2019-2023 | |
| Allergan, INC. | $171.09 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $158.18 | 2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.